Compare Natera Inc. Common Stock (NTRA) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs VanEck Rare Earth/Strategic Metals — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while VanEck Rare Earth/Strategic Metals trades at $54.51 (market cap $1.64B). The key difference: Natera Inc. Common Stock is far larger — about 34.8× VanEck Rare Earth/Strategic Metals's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and VanEck Rare Earth/Strategic Metals for 52 Days on average.
| NTRA | REMX | |
|---|---|---|
Market Cap | $57.03B | $1.64B |
Volume | 1,131,157 | 710,568 |
Sector | Health | Sector/Thematic |
52-Week High | $425.64 | $109.53 |
52-Week Low | $179.42 | $55.78 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $57.45, down 1.25% amid bearish technical signals with moving averages indicating strong selling pressure. The ETF provides exposure to 38 global rare earth companies but faces high volatility and China concentration risks. Recent institutional activity includes Bank of America increasing its position by 72.1% in Q2 2026, while geopolitical developments around critical minerals supply chains continue to influence sentiment.
The outlook remains challenged by technical weakness and sector volatility, though oversold RSI readings suggest potential near-term bounce. Long-term prospects hinge on U.S. supply chain development and China export policies, but the ETF's 50% annualized volatility makes it unsuitable for conservative investors. Strategic importance of rare earths supports thematic interest despite execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
